Sanofi and Re­gen­eron eye younger pa­tients for Dupix­ent amid ris­ing tide of ri­vals in atopic der­mati­tis

With a suite of ri­vals turn­ing up the heat in atopic der­mati­tis, Sanofi and Re­gen­eron are look­ing to keep their com­pet­i­tive edge with a la­bel ex­pan­sion to an even younger pop­u­la­tion — and the FDA has promised to give their ap­pli­ca­tion a swift re­view.

Dupix­ent was grant­ed pri­or­i­ty re­view for the treat­ment of AD in kids 6 months to 5 years old, Sanofi and Re­gen­eron an­nounced on Thurs­day. The megablock­buster is cur­rent­ly the on­ly bi­o­log­ic ap­proved for kids as young as six — but with grow­ing pres­sure from com­pa­nies like Eli Lil­ly and Pfiz­er, the new in­di­ca­tion would be a wel­come ad­vance for Sanofi and Re­gen­eron.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER